NCT07645820 Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
| NCT ID | NCT07645820 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Castle Biosciences Incorporated |
| Condition | Atopic Dermatitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2026-05-29 |
| Primary Completion | 2027-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2026-05-29 with a primary completion date of 2027-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic diary entries, and up to five in-person study visits. The study is based on the idea that changes in skin barrier function may occur before an AD flare becomes visible or symptoms begin. Information collected during the study, including device measurements, diary entries, and investigator assessments, will be used to evaluate whether these changes may help estimate the likelihood of an AD flare before visible signs or symptoms occur.
Eligibility Criteria
Inclusion Criteria: Participants may be eligible if they: * Are 12 to 89 years old. * Have been diagnosed with atopic dermatitis (eczema). * Have had at least one atopic dermatitis flare within the past 2 months. * Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits. * If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study. Exclusion Criteria: Participants may not be eligible if they: * Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements. * Do not have suitable skin areas for study measurements. * Have another skin condition that may affect study assessments. * Are pregnant.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07645820 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 89 Years, studying Atopic Dermatitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07645820 currently recruiting?
Yes, NCT07645820 is actively recruiting participants. Contact the research team at cjohnson@castlebiosciences.com for enrollment information.
Where is the NCT07645820 trial being conducted?
This trial is being conducted at Phoenix, United States, Las Vegas, United States, Portsmouth, United States, Missouri City, United States.
Who is sponsoring the NCT07645820 clinical trial?
NCT07645820 is sponsored by Castle Biosciences Incorporated. The trial plans to enroll 450 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.